Tumour-associated macrophages secrete IL-6 and MCP-1 in head and neck squamous cell carcinoma tissue

Kenneth W Kross1, John-Helge Heimdal, Carla Olsnes

  • 1Section for Otorhinolaryngology and Head and Neck Surgery, Institute of Surgical Science, Bergen, Norway. kenneth.kross@kir.uib.no

Acta Oto-Laryngologica
|April 25, 2007
PubMed

Insights

Tumour-associated macrophages in head and neck squamous cell carcinomas secrete IL-6 and MCP-1. L-leucine-methylester (LLME) reduced these secretions, indicating a potential therapeutic target.

Area of Science:

  • Oncology
  • Immunology
  • Cell Biology

Background:

  • Tumour-associated macrophages (TAMs) are crucial in malignant tumour progression.
  • Identifying the specific cytokine-secreting cells within tumours is essential.
  • TAMs are implicated in tumour cell growth and immune cell recruitment.

Purpose of the Study:

  • To investigate whether TAMs in head and neck squamous cell carcinomas (HNSCCs) secrete IL-6 and MCP-1.
  • To determine if L-leucine-methylester (LLME) can down-regulate these secretions.

Main Methods:

  • Utilized F-spheroids derived from HNSCC tissue fragments.
  • Incubated some F-spheroids with LLME to inhibit phagocyte function.
  • Quantified IL-6 and MCP-1 secretion using ELISA and compared between treated and untreated groups.

Main Results:

  • LLME treatment did not compromise F-spheroid viability.
  • LLME significantly reduced IL-6 and MCP-1 secretion from monocyte-derived macrophages in vitro.
  • F-spheroids from LLME-treated tissue fragments exhibited lower IL-6 and MCP-1 secretion.

Conclusions:

  • TAMs in HNSCCs secrete IL-6 and MCP-1.
  • LLME effectively down-regulates IL-6 and MCP-1 secretion by TAMs.
  • No qualitative functional difference was observed between TAMs and mucosal tissue macrophages regarding these cytokines.